Stock Exchange & Press Releases 2023

Print Print this release
October 26, 2023

Bittium Partners with ResMed to Offer Advanced Home Sleep Apnea Test and Analysis to Hospitals and Care Centers

Bittium Corporation
Press Release

Bittium Partners with ResMed to Offer Advanced Home Sleep Apnea Test and Analysis to Hospitals and Care Centers

Bittium Corporation, Press Release on October 26, 2023, at 3.00 p.m. (CEST +1)

Bittium Biosignals Ltd, a subsidiary of Bittium Corporation, and ResMed have signed an agreement under which ResMed becomes a distributor of Bittium Respiro™ the advanced Home Sleep Apnea Test and Analysis Solution. The solution includes Bittium Respiro™ measuring device and its accessories, as well as Bittium Respiro Analyst™ software analysing tool and service platform. The agreement is non-exclusive covering the United Kingdom, Republic of Ireland, Switzerland, Finland, Norway, and Sweden.

ResMed is a global leader of cloud-connected medical devices that transform care for those managing sleep apnea, COPD, and other chronic illnesses. Specifically addressing sleep apnea, ResMed delivers cloud-connected CPAP machines, equipment, and digital healthcare solutions, dedicated to enhancing the well-being of individuals with respiratory conditions and related chronic conditions through cutting-edge technology and comprehensive support.

Sleep apnea is a prevalent sleep disorder that often goes undiagnosed, leading to a range of health complications. According to research, there are more than 936 million people worldwide with obstructive sleep apnea [1]. Traditional methods of diagnosis involve spending a night in a sleep laboratory for a polysomnography study, making the process inconvenient and costly. Bittium Respiro™ focuses on night-time polygraphy (PG level) measurement performed at home. The solution captures and evaluates common instances of sleep-disordered breathing, employing artificial intelligence to enhance the efficiency of the analysis process. Bittium Respiro™ conducts a preliminary analysis of the data collected during the home study, transforming it into a visually informative format. This solution streamlines the clinical team's workflow for subsequent analysis and diagnosis.

In December 2022, Bittium Respiro™ received CE approval (MDR), becoming one of Europe's initial sleep apnea testing devices to receive this certification. The European Union's Medical Devices Regulation (MDR) outlines criteria for medical device manufacturers, importers, distributors, and authorized representatives to ensure device compliance, safety, and traceability.

“We are very excited about collaborating with a prominent industry leader. ResMed stands as a pioneer in delivering inventive medical devices and solutions, centered around enhancing respiratory health and wellbeing,“ says Mr. Antti Näykki, Senior Vice President, Bittium Medical Technologies Business Unit, and continues “Bittium Respiro offers a state-of-the-art solution designed for home sleep apnea testing and analysis that offers a user-friendly and convenient alternative to traditional in-lab studies. Recent clinical studies have yielded highly positive feedback, commending the solution's technical capabilities, analysis quality, and ease of use.”

“We are pleased to commence our partnership with Bittium. Bittium's technology facilitates an economical approach to sleep apnea diagnostics. With its CE-approved Bittium Respiro solution, we now have a location-independent solution for screening and diagnosing sleep apnea in the United Kingdom, the Republic of Ireland, Switzerland, Finland, Norway, and Sweden. This valuable addition enhances and supplements our current range of solutions for sleep apnea management,” says Andrew Huxter, General Manager Northern Europe at ResMed.

Further information:

Antti Näykki
Senior Vice President, Medical Technologies, Bittium
Tel. +358 40 344 3507
Email: [email protected]

Main media


In the field of healthcare technology, Bittium offers solutions for the measurement and monitoring of biosignals in the areas of cardiology, neurophysiology, and sports medicine. In addition, Bittium specializes in the development of reliable, secure communications and connectivity solutions, leveraging its 35-year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, and customized solutions based on its product platforms and R&D services. Bittium’s net sales in 2022 were EUR 82.5 million and operating profit was EUR 0.3 million. Bittium is listed on the Nasdaq Helsinki Exchange.   

[1] Benjafield et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respiratory Medicine 2019.